Study finds greater potential benefit in overall survival for eribulin compared with capecitabine
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, ...
Jun 12, 2013
0
0